While 22 states have sued the Trump Administration to temporarily block a major policy change by the National Institute of ...

Bio, Inc. (NASDAQ:THRD), a clinical-stage biopharmaceutical company with a market capitalization of $209.5 million, today announced positive Phase 1 clinical trial results for its drug candidate ...

CHICAGO - Cosmos Health Inc. (NASDAQ:COSM), a global healthcare group with a market capitalization of $15.11 million, is ...

We recently compiled a list of the 10 Best Long Term ASX Stocks to Buy Now. In this article, we are going to take a look at ...

Dana-Farber Cancer Institute researchers will present important research studies during the 2025 ASCO Genitourinary (GU) ...

Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report) have been assigned an average recommendation of “Buy” ...

BD affects millions but remains misunderstood, underdiagnosed, and underfunded. Researchers are working to change this by ...

We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...

Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be ...

The Oxford Vaccine Group, led by Prof Andrew Pollard, is renowned for collaborating with Oxford’s Jenner Institute in ...

Investment analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Zymeworks in a note issued to ...

Chemoradiation with platinum-based chemo is standard for locally advanced cervical cancer, but adverse events drive ...